SAM Holdings Widens Net Loss in FY24 on Higher Finance Costs
SAM Holdings Widens Net Loss in FY24 on Higher Finance Costs
In contrast, the group's revenue rose by 3% YoY to $16.6m in FY24 driven by growth in radiation therapy and oncology services due to the introduction of its proton beam therapy.Loss per share was at $0.0480.
每股虧損爲$0.0480。
The Singapore Institute of Advanced Medicine (SAM Holdings) reported a net loss of $37.4m in FY24, a 106.6% increase from a net loss of $18.1m in FY23.
愛文思控股新加坡醫療學院（SAm Holdings）財年24報告淨虧損3740萬美元，較財年23淨虧損1810萬美元增長106.6%。
It widened losses due to increased finance costs, high depreciation on new proton therapy equipment, and a decline in medical diagnostics revenue amidst strong market competition.
由於財務成本增加、新質子治療設備折舊高和醫療診斷營業收入在激烈市場競爭中下降，造成虧損加大。
In contrast, the group's revenue rose by 3% YoY to $16.6m in FY24 driven by growth in radiation therapy and oncology services due to the introduction of its proton beam therapy.
相反，集團的營業收入由於放射治療和腫瘤醫療服務增長，財年24年同比增長3%至1660萬美元，這是由於引入質子束治療設備。
The company's basic and diluted loss per share increased to $0.0480 from $0.0279 in FY23.
公司的基本和攤薄每股虧損從財年23的$0.0279增加至$0.0480。
譯文內容由第三人軟體翻譯。
